Biofrontera

Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454) in August 2020. Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each were issued. The term of the Bonds began on August 20, 2020 and will end on December 20, 2021. Pursuant to Section 8 (2) of the Bond terms and conditions, however, the Company is entitled to a mandatory conversion at any time without limitation in time after the price of the Company's share has exceeded EUR 4.50 ("Mandatory Conversion Trigger Price"). The Mandatory Conversion Trigger Price was exceeded after the commencement of the term of the Bonds.

Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.00), which beat the estimate of ($0.34).

Biofrontera: Q3 Earnings Insights

Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September 22, 2020, the German Federal Supreme Court has overturned a decision by the Cologne Higher Regional Court dated November 15, 2018, which was directed against the Company. The case was referred back to the Cologne Higher Regional Court for retrial and decision. Biofrontera AG has now received the statement of reasons of the German Federal Supreme Court regarding the reversal of the ruling by the Cologne Higher Regional Court.

Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court

Leverkusen, Germany, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2020.

Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020

Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics study (PK study) to test the safety of photodynamic therapy (PDT) using three tubes of Ameluz® at the same time.

Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study

Leverkusen, Germany, Sept.  22, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that in ruling on September 22, 2020, the German Federal Supreme Court overturned a decision by the Cologne Higher Regional Court dated November 15, 2018, which was directed against the Company. The overturned ruling of the Cologne Higher Regional Court concerned an action for rescission and annulment brought by the shareholder Deutsche Balaton AG against certain resolutions of the Annual General Meeting held on May 24, 2017. The matter has now been referred back to the Cologne Higher Regional Court for retrial and decision. The reasons for the ruling of the Federal Supreme Court are currently not available to the Company.

Biofrontera AG: German Federal Supreme Court overturns ruling of the Cologne Higher Regional Court

Leverkusen, Germany, Sept.  11, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today has reached a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsche Balaton AG on the key elements of a mediation agreement. The completion of the mediation agreement is expected today.

Biofrontera AG plans mediation to resolve (legal) disputes

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2020 Results - Earnings Call Transcript

Leverkusen, Germany, Aug.  26, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the first six months ended June 30, 2020. In addition, the Company provided an overview of the current business performance.

Biofrontera report results for the first six months of 2020

Leverkusen, Germany, Aug.  20, 2020  (GLOBE NEWSWIRE) --  On August 18, 2020,  Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with gross proceeds of EUR 7.9 million. Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds (the "Bond") were issued. The subscription price equaled 100% of the nominal value, corresponding to EUR 3.00 per Bond.

Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021

Leverkusen, Germany, Aug.  19, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2020 on Wednesday, August 26, 2020.

Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results

Leverkusen, Germany, Aug.  18, 2020  (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150 1.00% qualified subordinated mandatory convertible bonds 2020/2021 ("Bonds") with pre-emptive subscription rights for shareholders. The subscription price was set at 100% of the nominal value, corresponding to EUR 3.00 per Bond. As already announced to the capital market at the end of the subscription period on August 13, 2020, it had become apparent that all of the Bonds would be placed. This was confirmed after the completion of the private placement, following which the offering was significantly oversubscribed. The gross proceeds from the capital measure amount to EUR 7.9 million.

Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021

Leverkusen, Germany, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with pre-emptive subscription rights for shareholders. 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each (ISIN: DE000A3E4548 / WKN: A3E454) were offered for subscription at a subscription or placement price of 100% of their nominal value, corresponding to EUR 3.00 each in cash. The subscription period ends on August 13, 2020.

Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021

Leverkusen, Aug.  10, 2020  (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454). It is divided into up to 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each and a total nominal value of up to EUR 7,914,450. The shareholders or holders of subscription rights were invited by an announcement in the Federal Gazette (Bundesanzeiger) of 29 July 2020 to exercise their subscription rights to the Bonds during normal business hours in the period from 30 July 2020 up to 13 August 2020 (included) to avoid exclusion. It was also provided that the subscription price would be published in the Federal Gazette (Bundesanzeiger) and via an electronic information medium no later than three days before the end of the subscription period.

Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021

Leverkusen, Germany, July  27, 2020  (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory Board, to issue a qualified subordinated mandatory convertible bond subject to the granting of statutory subscription rights.

Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds

Leverkusen, Germany, July  23, 2020  (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced that the appointments and service contracts of both members of the Management Board, CEO Prof. Dr. Hermann Lübbert and CFO Thomas Schaffer, have each been extended for an additional 2 year-term.

Supervisory Board of Biofrontera AG renews Management Board appointment

Leverkusen, Germany, July  14, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first six months of fiscal year 2020.

Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020

Leverkusen, Germany, June  30, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the financing requirements to maintain ongoing business operations. 

Biofrontera confirms financing need

Leverkusen, Germany, May  28, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, an international biopharmaceutical company, announces the results of the Annual General Meeting (AGM) held today on May 28, 2020. The shareholders present represented 76.31% of the registered share capital.

Results of the 2020 Annual General Meeting of Biofrontera AG

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q1 2020 Results - Earnings Call Transcript

Leverkusen, May  19, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent developments.

Biofrontera reports Q1 2020 financial results

Leverkusen, Germany, May  13, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today comments on certain litigation in California state court between the Company and DUSA Pharmaceuticals, Inc. (“DUSA”).

Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2019 Results - Earnings Call Transcript

Leverkusen, Germany, April  20, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2019 and provided an update on recent operational and clinical developments.

Biofrontera Reports Full Year 2019 Financial Results

Leverkusen, Germany, April  20, 2020  (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has signed today an exclusive license agreement (the "Agreement") with Maruho Co, Ltd, Osaka, Japan ("Maruho") for the development and commercialization of Ameluz® for all indications in East Asia and Oceania, based on the term sheet agreed on March 3, 2020 (see ad hoc release of March 3, 2020).

News for Biofrontera Stock (BFRA)